Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:37:22.531Z.
Calculation as of: 2026-10-06T19:37:22.531Z.
Quote observation: 2026-10-06T19:35:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$256.77M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$256.68M
EBITDA Yield
0.21%
TTM Avg
12.97%
3Y Avg
7.82%
5Y Avg
5.93%
Market Cap
$258.80M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.17M
EBITDA Yield
N/A
TTM Avg
10.04%
3Y Avg
10.04%
5Y Avg
9.67%
Market Cap
$261.28M
EBITDA Yield
N/A
TTM Avg
55.26%
3Y Avg
33.09%
5Y Avg
19.40%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $256.77M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.68M | 0.21% | 12.97% | 7.82% | 5.93% |
| AC Immune S.A. (ACIU)vs › | $257.37M | N/A | 11.24% | 13.49% | 12.26% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.80M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.85M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.17M | N/A | 10.04% | 10.04% | 9.67% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | N/A | 0.00% | 0.00% | 0.00% |
| OraSure Technologies, Inc. (OSUR)vs › | $261.28M | N/A | 55.26% | 33.09% | 19.40% |
| Upstream Bio, Inc. (UPB)vs › | $251.10M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
